Lead study investigator Scott Donaldson, M.D., Associate Professor of Medicine, University of North Carolina at Chapel Hill, presented "VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: interim analysis," during Workshop 7 - Novel Therapies on June 13, 2013.
Lead study investigator Michael P. Boyle, M.D., F.C.C.P., Associate Professor, Director of the John Hopkins Adult Cystic Fibrosis Center, presented "Lumacaftor, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in CF patients with the F508Del-CFTR mutation: Phase 2 interim analysis," during Workshop 7 - Novel Therapies on June 13, 2013.